# A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System

Study · id `cardio:ct-nct07194265` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07194265](<https://clinicaltrials.gov/study/NCT07194265>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07194265

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1650 participants.

## Technical summary

Registry record NCT07194265. Randomized; single masking; primary purpose treatment. Start 2025-10-21 (actual); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1650 participants (planned count; ClinicalTrials.gov record NCT07194265, source copy `cardio:ctgov-nct07194265-2026-07-15`, retrieved 2026-10-26)
- Started: 2025-10-21 (actual) (ClinicalTrials.gov record NCT07194265, source copy `cardio:ctgov-nct07194265-2026-07-15`, retrieved 2026-10-26)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT07194265, source copy `cardio:ctgov-nct07194265-2026-07-15`, retrieved 2026-10-26)
- Completion: 2038-03 (anticipated) (ClinicalTrials.gov record NCT07194265, source copy `cardio:ctgov-nct07194265-2026-07-15`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT07194265, source copy `cardio:ctgov-nct07194265-2026-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07194265-2026-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System
- Acronym: PARADIGM
- Condition: Severe Aortic Stenosis
- Condition: Valve-in-valve Procedures
- Intervention (Device): TAVR with DurAVR® THV
- Intervention (Device): TAVR with SAPIEN THV series or the Evolut THV series
- Lead sponsor: Anteris Technologies Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 527fa9dfe4a48d4162c9a139c0d2402bcad55e8e4b4b7b6b8328df642865e247
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
